Candel director granted 32,000 stock options
Candel Therapeutics director Edward J. Benz Jr. received a grant of stock options covering 32,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Candel Therapeutics director Edward J. Benz Jr. received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $9.08 per share and expire on June 23, 2036.
The award is subject to time-based vesting, becoming exercisable on the earlier of June 23, 2027 or the next Annual Meeting of Stockholders, as long as he continues serving on the board unless the board decides otherwise. Following this grant, he holds 32,000 stock options directly.
Insider Trade Summary
Grant/Award: 32,000 shares
Grant/Award
1 txn
Insider
Benz Edward J. JR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 32,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 32,000 contracts (Direct)
Footnotes (1)
- F1. This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
Key Figures
Options granted: 32,000 options
Exercise price: $9.08 per share
Expiration date: June 23, 2036
+3 more
6 metrics
Options granted
32,000 options
Stock Option (Right to Buy) grant on June 23, 2026
Exercise price
$9.08 per share
Conversion/exercise price of granted stock options
Expiration date
June 23, 2036
Option expiration for 32,000-share grant
Underlying shares
32,000 shares
Common stock underlying the stock option grant
Post-grant option holdings
32,000 options
Total stock options held following this transaction
Vesting date trigger
June 23, 2027
Time-based vesting, or earlier next Annual Meeting of Stockholders
Key Terms
Stock Option (Right to Buy), time-based vesting, Annual Meeting of Stockholders, Board of Directors, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
time-based vesting financial
"This option is subject to time-based vesting."
Time-based vesting is a schedule that gives employees or contractors ownership of granted stock or options gradually as they remain with a company, like unlocking rewards in a loyalty program the longer you stick around. For investors, it matters because it affects future share supply, management incentives and staff retention — all of which can influence company performance and dilution of existing shareholders.
Annual Meeting of Stockholders financial
"the date of the next Annual Meeting of Stockholders of the Issuer"
Board of Directors financial
"resigns from the Board of Directors (the "Board") of the Issuer"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
derivative securities financial
"Grant, award, or other acquisition of derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Candel Therapeutics (CADL) report for Edward J. Benz Jr.?
Candel Therapeutics reported that director Edward J. Benz Jr. received a grant of stock options for 32,000 shares. These options are a compensation award, not an open-market purchase or sale, and give him the right to buy common stock at a fixed exercise price.
What is the exercise price of the new CADL stock options granted to the director?
The granted stock options have an exercise price of $9.08 per share. This means the director can buy Candel Therapeutics common stock at $9.08 if the options vest and are exercised before they expire in 2036, regardless of the market price at that time.
When do Edward J. Benz Jr.’s CADL stock options vest?
The options vest on the earlier of June 23, 2027 or the date of the next Annual Meeting of Stockholders. Vesting also depends on his continued service on Candel Therapeutics’ board, unless the board determines vesting should continue despite a change in his status.
When do the newly granted CADL stock options expire?
The stock options granted to Edward J. Benz Jr. expire on June 23, 2036. If they are not exercised by that date, the right to purchase 32,000 shares at the $9.08 exercise price will lapse and the options will no longer be exercisable.
How many CADL stock options does the director hold after this Form 4 transaction?
After this transaction, Edward J. Benz Jr. holds 32,000 stock options directly. All of these options relate to Candel Therapeutics common stock and are subject to the time-based vesting conditions and the 2036 expiration date described in the Form 4 filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates